| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Pseudomonas aeruginosaAlginateCystic fibrosisAcinetobacter baumanniiESBLAntibiotics (Resistance)Carbapenemase| 1 | 2005 | Aminoglycoside resistance in Pseudomonas aeruginosa. | 
| + | - | nl | Antimicrob Agents Chemother 49(2):479-87 (2005) |
| 2 | 1991 | Antimicrobial agent therapy for Pseudomonas aeruginosa. |
| + | - | nl | Antimicrob Agents Chemother 35(11):2167-72 (1991) |
| 3 | 2009 | Update on the treatment of Pseudomonas aeruginosa pneumonia. |
| + | - | nl | J Antimicrob Chemother 64(2):229-38 (2009) |
| 4 | 1999 | Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. |
| + | - | nl | Microbiol Mol Biol Rev 63(3):523-53 (1999) |
| 5 | 1971 | Regulation of catabolic pathways in Pseudomonas. |
| + | - | nl | Bacteriol Rev 35(2):87-116 (1971) |
| 6 | 1969 | Genetics of Pseudomonas. |
| + | - | nl | Bacteriol Rev 33(3):419-43 (1969) |
| 7 | 1991 | Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. |
| + | - | nl | Clin Microbiol Rev 4(2):191-206 (1991) |
| 8 | 2008 | Pseudomonas 2007. |
| + | - | nl | J Bacteriol 190(8):2649-62 (2008) |
| 9 | 2007 | Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. |
| + | - | nl | Clin Microbiol Infect 13(6):560-78 (2007) |
| 10 | 2005 | Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. |
| + | - | nl | Clin Microbiol Infect 11 Suppl 4(-):17-32 (2005) |
| 11 | 2005 | Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. |
| + | - | nl | Mol Microbiol 56(2):309-22 (2005) |
| 12 | 2006 | The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. |
| + | - | nl | J Med Microbiol 55(Pt 12):1619-29 (2006) Falagas ME |
| 13 | 2005 | Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. |
| + | - | nl | Am J Respir Crit Care Med 171(11):1209-23 (2005) |
| 14 | 2000 | Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. |
| + | - | nl | Eur Respir J 16(4):749-67 (2000) Doring G |
| 15 | 2011 | Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. |
| + | - | nl | Mayo Clin Proc 86(3):250-9 (2011) |
| 16 | 2009 | Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. |
| + | - | nl | Clin Microbiol Rev 22(4):582-610 (2009) |
